How the US 'America First' Health Strategy Trades Aid for Data Sovereignty in Global Health

For decades, global health assistance was marketed primarily as an act of humanitarian charity, a one-way flow of funds designed to eradicate disease and build goodwill. But the newly implemented America First Global Health Strategy (AFGHS) strips away that diplomatic veneer, making the transactional nature of modern medical funding explicit. The United States is now offering continued financial support for vital health programs—such as HIV/AIDS mitigation—in direct exchange for access to recipient nations' electronic medical records, pathogen samples, and genomic data.[1][6]

This represents a profound shift from the legacy of the President's Emergency Plan for AIDS Relief (PEPFAR). Launched in 2003, PEPFAR operated as a massive, relatively low-cost humanitarian commitment that ultimately saved an estimated 25 million lives. Under the new strategy, however, the roadmap charts a path of declining unconditional support. Recipient countries are now required to provide progressively higher co-investment for frontline healthcare workers and medical commodities to maintain their bilateral partnerships with Washington.[1][2]

The most contentious element of this new playbook is the data conditionality. Under the AFGHS template, partner governments are asked to sign Memorandums of Understanding that grant U.S. agencies deep access to their national health information systems. This effectively bypasses established multilateral data-sharing frameworks, such as the World Health Organization's Pathogen Access and Benefit Sharing system, in favor of direct, country-to-country agreements that heavily favor the primary funder.[1][6]

Washington frames this data-access requirement as a non-negotiable biosecurity necessity. Proponents argue that the COVID-19 pandemic exposed the fatal flaws of relying on voluntary, delayed data sharing through multilateral institutions. By tying funding directly to data access, the U.S. ensures it has the real-time epidemiological intelligence required to secure its own borders, monitor emerging pathogens, and protect the supply chains for critical medical commodities.[2][6]

Yet there is a glaring geopolitical tension at the heart of this policy. Even as the U.S. demands access to the health data of aid-recipient nations, it is aggressively shielding its own citizens' genomic information from foreign eyes. Following the passage of the BIOSECURE Act and a series of executive orders, Washington has strictly limited the transfer of Americans' bulk sensitive personal data—specifically citing genomic and health data—to countries of concern, framing such transfers as a severe national security risk.[4][6]

This dual approach has sparked a fierce pushback from the Global South, centered on the rapidly growing concept of digital and data sovereignty. African nations, coordinated by the Africa CDC, argue that the current global health architecture extracts valuable epidemiological and genomic data without guaranteeing fair benefit-sharing. When data is transferred to centralized Western servers, local researchers lose agency over the information they generated, and the resulting medical innovations are rarely priced accessibly for the contributing populations.[3][5]

The Africa CDC has formally called for African Health Sovereignty, demanding that equity become a binding operating principle in all global health agreements. This movement insists on mandating technology transfer, expanding regional manufacturing, and ensuring that local data sharing directly improves local outbreak responses. The push for digital sovereignty reflects a broader frustration with an aid model that many leaders view as conditional and extractive rather than genuinely collaborative.[3][6]

The lived experience of recent epidemics fuels this frustration. During the mpox outbreaks of 2022 and 2024, African nations provided the foundational pathogen data and epidemiological tracking that alerted the world to the threat. Yet, when vaccines and therapeutics were developed and distributed, high-income countries secured the supplies, leaving the endemic regions waiting. For many health ministries, this dynamic proved that sharing data without binding benefit-sharing agreements is a losing proposition.[3][6]

Beyond the immediate public health implications, there is a massive economic stakes in who controls this data. Health and pathogen data extracted under these bilateral agreements can be used to train highly lucrative Western artificial intelligence models or support advanced pharmaceutical research. Without enforceable safeguards, there is no guaranteed return to the contributing countries in the form of subsidized products, shared intellectual property, or economic royalties.[1][5]

However, a skeptical look at the technical reality reveals a massive gap between the political announcements in Washington and the shipped capabilities on the ground. While the AFGHS MOUs demand seamless access to health information systems, setting up interoperable, secure data pipelines in low-resource settings is a monumental engineering challenge. The marketing language of shared biosecurity often ignores the friction of fragmented electronic health records and incompatible digital infrastructure.[5][6]

In many recipient countries, health data is siloed across different regional systems, non-governmental organizations, and legacy software platforms. Furthermore, severe data-sharing frictions and geopolitical tensions around data privacy have already stalled critical U.S. bilateral agreements in nations like Nigeria, Zambia, and Ghana. The access granted on paper frequently fails to materialize into the clean, real-time intelligence that U.S. predictive models require.[5][6]

To resolve this standoff, the global health research community is increasingly pivoting toward a technical compromise known as Collaborative Data Sovereignty. Instead of forcing nations to transfer sensitive health data to central U.S. repositories—which triggers both political resistance and legal hurdles—this model utilizes federated analytics and privacy-preserving computation. The raw data remains securely under the stewardship of the host country's institutions.[5]

In a federated learning system, the analytical models travel to the data, rather than the data traveling to the analyst. U.S. researchers and biosecurity algorithms can query the local servers, train their predictive models on the genomic and epidemiological data, and extract the necessary insights without ever moving the underlying raw files across international borders. This approach satisfies the U.S. need for rapid intelligence while respecting the host nation's legal sovereignty.[5][6]

Advances in privacy-preserving computation have made this federated approach technically feasible at scale. It effectively neutralizes the primary argument against data sharing by ensuring that the ultimate custodianship of health data rests with the relevant public bodies and the citizens they serve. By defining data based on open, vendor-neutral specifications, nations can build health infrastructure that aligns with their specific governance requirements.[5]

Crucially, this model aligns research collaboration with long-term capacity strengthening. When data remains local, institutions are forced to develop the systems, governance structures, and analytical expertise required to manage it. Over time, this builds sustainable analytical capacity and supports scientific leadership in the Global South, shifting roles from mere data collection to active evidence generation.[5][6]

The transition to federated analytics also enables better science. Researchers who are closest to the data and the communities it represents are often best placed to ask meaningful, contextually grounded questions. Empowering local scientists to lead the analysis increases the relevance, quality, and uptake of research into clinical practice, ultimately making the global health system more resilient.[5]

The America First Global Health Strategy represents a critical inflection point in medical diplomacy. If the United States insists on centralized data extraction as a hard condition for aid, it risks alienating partner nations, stalling vital health programs, and driving emerging economies toward competing geopolitical blocs that offer funding with fewer digital strings attached.[3][6]

Ultimately, embracing collaborative data sovereignty offers a viable path forward. It allows the U.S. to achieve its core biosecurity goals without replicating the extractive dynamics of the past. By treating data sovereignty not as an obstacle to overcome, but as a foundational right to respect, the global community can forge a more equitable and functional health architecture for the next era of pandemic preparedness.[5][6]